SynthesisImmunity, inflammation and disease2026
Research Progress on Anti-Inflammatory Adipokine SFRP5-Mediated Lipid Metabolism and Its Potential Role in Neural Development.
Synthesis in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Research Progress on Anti-Inflammatory Adipokine SFRP5-Mediated Lipid Metabolism and Its Potential Role in Neural Development.Immunity, inflammation and disease · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
objectiveTo systematically review the structural features of secreted frizzled‑related protein 5 (SFRP5) and its dual regulation of canonical/non‑canonical Wnt signaling, analyze its association with metabolic disorders, and specifically explore the role and mechanisms of the SFRP5-lipid metabolism axis in neural and optic nerve development.
methodsA systematic literature search was performed to review the molecular structure of SFRP5, its regulation of Wnt pathways, and its relationship with metabolic dysregulation. The mechanisms by which SFRP5 modulates the microglia/astrocyte‑mediated neuroimmune microenvironment, myelination, synaptic plasticity, and neuronal mitochondrial energy homeostasis were analyzed, and current therapeutic strategies targeting the SFRP5 network were summarized.
resultsSFRP5 participates in normal central nervous system development by shaping the neuroimmune microenvironment, promoting myelination, regulating synaptic plasticity, and maintaining mitochondrial energy balance. Under obese and diabetic conditions, downregulation of SFRP5 leads to overactivation of Wnt5a/JNK signaling, resulting in lipid metabolic disturbances and neuroinflammation. These changes share common pathological features with neurodevelopmental disorders such as autism spectrum disorder, intellectual disability, optic nerve hypoplasia, and retinal vascular dysplasia. The SFRP5-lipid metabolism axis plays a critical role in neural and optic nerve development, and its dysregulation underlies the neuropathology associated with metabolic diseases. Therapeutic interventions explored to date-including recombinant protein, gene therapy, small‑molecule activators, and acupuncture-have shown promising potential.
conclusionThe SFRP5-lipid metabolism axis represents a key link connecting metabolic disorders with neurodevelopmental abnormalities. Future research should focus on spatiotemporal specificity at single‑cell resolution, elucidation of gene-environment interactions, and the development of efficient central nervous system delivery systems, thereby providing new avenues for the prevention and treatment of neural and optic nerve developmental abnormalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.